Clinical trial · Interventional
Autologous Immune Enhancement Therapy (AIET) for Cancer Patients
Evaluating Safety and Quality of Life of Cancer Patients Treated by Autologous Immune Enhancement Therapy (AIET) in Vinmec International Hospitals
NCT05520372CI-TRIAL-00060581completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective study that included 60 cancer patients who underwent autologous NK cell and CD8 T cell therapy between January 2016 and December 2021
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients With Cancer | Malignant Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Autologous immune enhancement therapy (AIET) for cancer patients | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- autologous immune enhancement therapy (AIET) for treating cancer
- description
- A total of 60 cancer patients received one to seven sittings of natural killer (NK) cells and cytotoxic T lymphocytes (CTLs) infusions.
- interventionNames
- Combination Product: Autologous immune enhancement therapy (AIET) for cancer patients
Primary outcomes (1)
- measure
- Number of Adverse events and serious adverse events (AEs or SAEs)
- timeFrame
- up to the 36-month period following treatment
- description
- the number of AEs or SAEs during and after Autologous Immune Enhancement Therapy (AIET)
Secondary outcomes (3)
- measure
- Changes in health-related quality of life of patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients aged 18 - 75 * Patients have been diagnosed with cancer. * Patients signed the written informed consent form. Exclusion Criteria: * Severe health conditions such as serious infection, autoimmune diseases, or using any anti-rejection drugs
References
Publications (0)
Data not yet available
No reference posted for this study.